Table 4 Tumor characteristics before and after propensity score matching
Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
ART n = 21 | Early SRT n = 64 | p | ART n = 21 | Early SRT n = 21 | p | |
Tumor stage | ||||||
≤T2c | 4 (19.0%) | 39 (60.9%) | 0.001* | 4 (19.0%) | 0 (0.0%) | 0.11 |
≥T3a | 17 (81.0%) | 25 (39.1%) | 17 (81.0%) | 21 (100.0%) | ||
Nodal status | ||||||
N0 | 20 (95.2%) | 63 (98.4%) | 0.44 | 20 (95.2%) | 20 (95.2%) | 1.00 |
N1 | 1 (4.8%) | 1 (1.6.%) | 1 (4.8%) | 1 (4.8%) | ||
Gleason score | ||||||
≤7a | 6 (28.6%) | 31 (48.4%) | 0.13 | 6 (28.6%) | 9 (42.9%) | 0.52 |
≥7b | 15 (71.4) | 31 (48.4%) | 15 (71.4) | 12 (57.1%) | ||
Missing | 0 (0.0%) | 2 (3.1%) | 0 (0.0%) | 0 (0.0%) | ||
Surgical margins | ||||||
R0 | 5 (23.8%) | 39 (60.9%) | 0.005* | 5 (23.8%) | 12 (57.1%) | 0.06 |
R1 | 16 (78.2%) | 25 (39.1%) | 16 (78.2%) | 9 (42.9%) | ||
Biochemical relapse | ||||||
no | 20 (95.2%) | 55 (85.9%) | n./a. | 20 (95.2%) | 16 (76.2%) | n./a. |
yes | 1 (4.8%) | 9 (14.1%) | 1 (4.8%) | 5 (23.8%) | ||